|

zolbetuximab Clinical Trials

6 actively recruiting trials across 2 locations

Also known as: IMAB362, VYLOY, Vyloy

Pipeline

Phase 2: 2Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Universitaire Ziekenhuizen KU Leuven1
  • Shanghai Zhongshan Hospital1
  • AstraZeneca1
  • Astellas Pharma Korea, Inc.1
  • Astellas Pharma Global Development, Inc.1

Indications

  • Cancer6
  • Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma2
  • Metastatic Gastric Adenocarcinoma or Cancer2
  • Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer2
  • Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer2

Other4 trials

A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer
Phase 1/2
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer
Phase 2
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
Phase 2

Phoenix, Arizona1 trial

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Research Site

Phase 3

Cerritos, California1 trial

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

TOI Clinical Research

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.